Journal
CIRCULATION JOURNAL
Volume 73, Issue 2, Pages 361-370Publisher
JAPANESE CIRCULATION SOC
DOI: 10.1253/circj.CJ-08-0817
Keywords
Arteriosclerosis; Pleiotropic effects; Rho-kinase; Small GTPases; Statins
Categories
Funding
- Japanese Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan
- Pharmaceutical Safety and Research of Japan
- Technology Agency, CREST, Tokyo, Japan
Ask authors/readers for more resources
Background The pleiotropic effects of HMG-CoA reductase inhibitors (statins) are thought to be mediated through inhibition of small GTP-binding proteins; however, it remains to be examined whether clinical concentrations/doses of statins actually exert them. Methods and Results In vitro studies with cultured human umbilical venous endothelial cells found that statins (atorvastatin, pitavastatin and pravastatin at 10 mu mol/L) had no inhibitory effects on RhoA/Rho-kinase or Ras, but atorvastatin and pitavastatin inhibited membrane Rac1 expression. In animal Studies of angiotensin II (AngII)-infused rats, atorvastatin showed only mild inhibitory effects on AngII-induced cardiovascular hypertrophy, whereas fasudil, a selective Rho-kinase inhibitor, significantly suppressed it. Statins had no inhibitory effects on RhoA/ Rho-kinase, but inhibited both membrane and GTP-bound Rac1 in the heart, whereas fasudil only inhibited Rho-kinase activity. Furthermore, the combination of atorvastatin and fasudil showed more effective inhibitory effects than fasudil alone. Finally, in studies of normal healthy volunteers, clinical doses of pravastatin or atorvastatin (20 mg/day for 1 week) significantly inhibited Rac1, but not RhoA/Rho-kinase activity, in circulating leukocytes. Conclusions The pleiotropic effects of statins, if any, at their clinical doses are mediated predominantly through inhibition of the Rac1 signaling pathway. (Circ J 2009; 73: 361-370)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available